ArticleVeterinarni medicina2025
Successful pregnancy of a Maine Coon queen despite feline mammary fibroadenomatous hyperplasia recurrence after treatment with aglepristone.
Article in Veterinarni medicina, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the disorders of the mammary gland in the queen is feline mammary fibroadenomatous hyperplasia (FMFH), caused by an increasing concentration of progesterone (P4) and some other local growth factors. It occurs mostly during puberty after the heat characterised by spontaneous or provoked ovulation, as a result of exogenous progesterone intake and sometimes during pregnancy. To diagnose a 14-month-old intact Maine Coon queen with extensive mammary gland hyperplasia, a clinical examination, analyses of the progesterone (P4) concentrations and ultrasound examination were performed. Feline mammary fibroadenomatous hyperplasia associated with a high P4 concentration after spontaneous ovulation was confirmed. After 24 days of therapy with a progesterone antagonist, aglepristone, the symptoms of FMFH resolved. After the next eight weeks, the queen was mated after the owner's decision. In the third week of pregnancy, a relapse was detected (mammary gland enlargement, pain, discomfort). At the same time, no abnormalities in the uterus or embryos were detected via ultrasound. The P4 concentrations were under regular control. For the next two weeks, only conservative treatment with NSAIDs was used. The queen spontaneously delivered six kittens without any difficulties or perinatal complications 67 days after the first mating. The cat previously treated with aglepristone for FMFH was successfully bred, but FMFH symptoms returned when progesterone concentrations increased during pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.